The plasma membrane tetraspan molecule MS4A4A is selectively expressed by macrophage-lineage cells, but its function is unknown. Here we report that MS4A4A was restricted to murine and human mononuclear phagocytes and was induced during monocyte-to-macrophage differentiation in the presence of interleukin 4 or dexamethasone. Human MS4A4A was co-expressed with M2/M2-like molecules in subsets of normal tissue-resident macrophages, infiltrating macrophages from inflamed synovium and tumor-associated macrophages. MS4A4A interacted and colocalized with the β-glucan receptor dectin-1 in lipid rafts. In response to dectin-1 ligands, Ms4a4a-deficient macrophages showed defective signaling and defective production of effector molecules. In experimental models of tumor progression and metastasis, Ms4a4a deficiency in macrophages had no impact on primary tumor growth, but was essential for dectin-1-mediated activation of macrophages and natural killer (NK) cell-mediated metastasis control. Thus, MS4A4A is a tetraspan molecule selectively expressed in macrophages during differentiation and polarization, essential for dectin-1-dependent activation of NK cell-mediated resistance to metastasis.
M
acrophages are central players in the pathophysiology of infections and cancer, being capable of adapting to the local microenvironment assuming a range of different phenotypes. During infections, macrophages sense pathogens through pattern recognition receptors and, via the release of immune mediators, orchestrate the activation of proinflammatory immune responses. This can be mimicked in vitro by the exposure to bacterial compounds and interferon-γ (IFN-γ), which promotes a classic activation of macrophages (M1), endowed with proinflammatory features. At the opposite side of a spectrum of activation phenotypes, interleukin 4 (IL-4) and other stimuli induce macrophages to acquire an alternative phenotype (M2) 1, 2 . Macrophages also coordinate immune responses by complex bidirectional interplay with other immune cells. In tumors, in particular, tumor-associated macrophages (TAMs) establish a network with tumor and host cells supporting a pro-tumoral microenvironment 3, 4 . TAMs promote tumor progression by different means, ranging from stimulation of angiogenesis to suppression of adaptive immune responses through the triggering of the activity of inhibitory immune checkpoint molecules, such as progression of disease ligand (PD-L)1, PD-L2 and VISTA 5 . Based on this, targeting of TAMs represents a major therapeutic option under investigation 3 . Several markers have been reported to identify specific macrophage subsets as well as distinct macrophage activation profiles [6] [7] [8] . The present study investigated in particular the expression and function of the tetraspan molecule membrane spanning four domains A4A (MS4A4A), which belongs to the transcriptional signature of M2-polarized macrophages and TAMs 6, 9 . MS4A4A was selectively expressed in tissue-resident macrophages and homeostatic as well as inflammatory conditions, and was highly expressed in TAMs, both in humans and in mice. MS4A4A functionally associated with dectin-1 in macrophage lipid rafts and was required for the full activation of the Syk-dependent signaling pathway, and the consequent production of cytokines and reactive oxygen intermediates on dectin-1 engagement. Although the macrophage-selective genetic inactivation of Ms4a4a had no impact on primary mesenchymal carcinogenesis and transplanted tumor growth, we found that Ms4a4a-deficient macrophages were impaired in their ability to support dectin-1-dependent cross-talk with NK cells, resulting in uncontrolled metastatic spread.
Results

MS4A4A expression is restricted to macrophages.
Transcriptomic data from us and others have previously identified MS4A4A as a putative marker of human macrophages undergoing IL-4-dependent alternative activation 6, 9 . When investigated at the protein level by flow cytometry, macrophages were the only leukocyte population scoring positively, whereas circulating myeloid (polymorphonuclear neutrophils, monocyte subsets, myeloid (mDCs) and plasmacytoid dendritic cells (pDCs)) and lymphoid cells (NK, NKT, T and B) scored negatively (Fig. 1a) . Monocyte-derived DCs did not express MS4A4A (see Supplementary Fig. 1a ,b) and were also negative for MS4A6A (see Supplementary Fig. 1c,d ) and MS4A7 (see Supplementary Fig. 1e,f) , two other members of the MS4A family highly expressed on macrophages 6 . In vitro, MS4A4A expression progressively increased during macrophage colony-stimulating factor (M-CSF)-dependent monocyte differentiation to macrophages (Fig. 1b) . When regulation of MS4A4A expression in mature macrophages was investigated, we first confirmed its induction in alternative macrophages activated by IL-4, but not by other stimuli inducing M2-like phenotypes such as transforming growth factor-β and IL-10 ( Fig. 1c) . We then identified the glucocorticoid hormone dexamethasone (Dex) as a second potent inducer of MS4A4A expression, alone or in combination with IL-4 ( Fig. 1c,d ). MS4A4A transcript abundance was increased by Dex treatment at 18 h, at which time a significant increase in MS4A4A protein expression was also detected (Fig. 1e,f ). Glucocorticoids were also demonstrated to act as potent MS4A4A inducers in vivo, because MS4A4A transcript levels were strongly upregulated in circulating monocytes isolated from patients with Graves' disease on acute exposure to methylprednisolone (Fig. 1g) . Conversely, Dex treatment was unable to induce expression of MS4A4A, MS4A6A or MS4A7 in monocyte-derived DCs (see Supplementary Fig. 1 ). Both in resting macrophages, and more prominently in macrophages activated by Dex and IL-4 in combination, MS4A4A expression was significantly enriched in the CD163 + macrophage subset, whereas its expression did not correlate with CD36 and CD206 expression (Fig. 1h) .
To define MS4A4A expression in tissues, we first interrogated the public gene expression database RefExA, which indicated pos monocytes, B cells and polymorphonuclear cells (PMN); eight for isotype (Iso) and macrophages (MΦ) (a); two donors for day 7 after M-CSF treatment, three for monocytes and day 3 after M-CSF treatment; four for day 1 and five after M-CSF treatment (b); three donors (c)). Statistical analysis by one-way ANOVA. d, MS4A4A expression on human macrophages treated with IL-4 plus Dex (Dex + IL-4) or not (Medium) for 18 h. DAPI staining of nuclei is shown in blue. Immunofluorescence images are representative of one experiment out of three biologically independently performed ones. e,f, Time-course of MS4A4A messenger RNA (e) and plasma membrane protein (f) in human macrophages treated with Dex for the indicated time. Results are shown as mean ± s.e.m. of fold-change (e) or relative MFI (f) (fold-change on M0). Two biologically independent experiments were performed (three donors for e and five for f). Statistical analysis by two-tailed, one-sample, Student's t-test. g, Expression levels of MS4A4A mRNA in monocytes isolated from three patients with Graves' disease orbitopathy before and 6 h after injection with 1 g methylprednisolone. Results are shown as fold-change on untreated cells (open columns). h, Flow cytometry analysis of macrophage plasma membrane expression of MS4A4A and other indicated M2 markers (CD36, CD163, CD206) in resting conditions (-) or after exposure for 18 h to IL-4+ Dex (+). Two biologically independent experiments were performed (four donors).
expression of the MS4A4A transcript in several normal human tissues (see Supplementary Fig. 2a ). Analysis of cell type-specific gene expression revealed that MS4A4A expression was restricted to macrophages (see Supplementary Fig. 2b ). In agreement with those data, immunohistochemical analysis detected MS4A4A expression in several human tissues, including colon, lung and skin (Fig. 2) . Also, in vivo, combined staining confirmed that MS4A4A expression was restricted to the CD163 + macrophages (Fig. 2b ,e,h). Importantly, lung pDCs (CD303 + ; Fig. 2c ), colon DCs (CD1c + ; Fig. 2f ) and skin Langerhans' cells (CD207 + ; Fig. 2i ) did not express MS4A4A. Finally, when MS4A4A expression was investigated in the synovium of early rheumatoid arthritis (RA) patients, a prototypic chronic inflammatory condition, again MS4A4A was predominantly expressed by a subset of CD163 + macrophages (Fig. 3a,b ) and was not detected in CD3 + T cells, CD20 + B cells or CD138 + plasma cells (Fig. 3c) infiltrating the inflamed synovium. Taken together, these results indicate that both in normal and in chronic inflammatory conditions MS4A4A expression is restricted to tissue-resident macrophages, where it is upregulated by IL-4 and glucocorticoid hormones.
MS4A4A is not functionally relevant for pro-tumoral functions of tumor-associated macrophages. The gene expression database The Cancer Genome Atlas (TCGA) also reported the MS4A4A transcript signature in a large number of human tumors (see Supplementary Fig. 3a ), although in some cases to a lower extent compared with corresponding normal tissues. Consistent with this, immunohistochemical analysis detected MS4A4A expression in melanoma, as well as in colon and lung tumors. Combined analysis confirmed that its expression was restricted to CD163 + TAMs (Fig. 4a,c,e ), in agreement with results obtained on in vitro differentiated human macrophages and in inflamed synovium. A strong correlation between MS4A4A and CD163 transcript levels and, to a minor extent, other M2/TAM markers, was also evident in the TCGA cancer dataset (see Supplementary Fig. 3b ). Importantly, tumor-associated DCs did not express MS4A4A (Fig. 4b,d,f) .
As the absence of a specific antibody prevented us from investigating the expression of mouse Ms4a4a protein, we evaluated Ms4a4a expression at the transcript level using quantitative PCR. Consistent with results obtained in the human setting, macrophages were the only leukocyte population present in mouse spleen with detectable Ms4a4a transcripts (see Supplementary Fig. 4a ). IL-4 or Dex, alone or in combination, strongly augmented Ms4a4a expression, whereas the M1-polarizing treatment with IFN-γ and lipopolysaccharide (LPS) failed to induce its expression (see Supplementary  Fig. 4b ). In line with abundant MS4A4A expression detected by immunohistochemistry in human TAMs, we detected elevated levels of the murine Ms4a4a transcripts in murine TAMs isolated from animals bearing LLC and B16F1 tumors, as well as xenograft tumors of the human kidney cancer cell line A498 (Fig. 4g) .
As Ms4a4a was highly expressed in murine TAMs, we investigated its functional relevance for carcinogenesis and tumor progression in different tumoral experimental models. To this purpose, mice with macrophage-selective deletion of Ms4a4a were generated. Ms4a4a expression was successfully abrogated in bone marrowderived macrophages (BMDMs) of Ms4a4a fl/fl Lys Cre/+ animals (indicated here as Ms4a4a -/-; see Supplementary Fig. 4c ), with no apparent phenotype or impact on the development for any immune cell subset (see Supplementary Fig. 4d ). When animals were tested, we found no difference in appearance, incidence and growth of primary tumors in mice with Ms4a4a-competent or -incompetent macrophages, neither in the B16F1 transplanted tumor model (Fig. 4h ) nor in a model of mesenchymal carcinogenesis based on 3-methylcholanthrene exposure (Fig. 4i,j) . We conclude that, although highly expressed in TAMs, Ms4a4a has no functional relevance for their ability to promote primary tumor growth, at least under the experimental conditions tested.
MS4A4A colocalizes with dectin-1 in lipid rafts. In search for a functional role of MS4A4A in macrophages, we considered the structural homology of MS4A proteins with tetraspanins, which are known to engage laterolateral interactions with other membrane proteins and influence their functional properties 10, 11 . By performing a split-ubiquitin, yeast, two-hybrid screening, an approach previously applied to identify partners of other MS4A members 12 , we identified membrane proteins interacting with MS4A4A. These included MS4A4A itself, as well as MS4A6A and MS4A7, two other MS4A family members highly expressed in alternative macrophages 6 , suggesting that, on the macrophage plasma membrane, these three MS4A members may interact with each other. We then validated the MS4A4A interaction with itself as well as the other two MS4A proteins in Chinese hamster ovary K1-transfected cells by fluorescence lifetime imaging microscopy-fluorescence resonance energy transfer (FLIM-FRET) analysis (Fig. 5a-c) , which indicates that these proteins likely organize in clusters on plasma membranes. Conversely, FLIM-FRET experiments did not reveal interaction of MS4A4A with the tetraspanins CD63 (Förster radius 1.24 ± 0.15 versus 1.27 ± 0.06 for vector-and MS4A4A-transfected cells, respectively; P > 0.05) and CD9 (Förster radius 1.28 ± 0.06 versus 1.26 ± 0.05 for vector-and MS4A4A-transfected cells, respectively; P > 0.05). Candidate MS4A4A interactors emerging from the split-ubiquitin yeast two-hybrid screening also included the membrane receptor for β-glucan dectin-1, the interaction of which with MS4A4A was confirmed by FLIM-FRET analysis (Fig. 5d) . Flow cytometry analysis indicated that macrophages had high coexpression of MS4A4A and dectin-1, both under resting conditions and on Dex treatment (see Supplementary Fig. 5 ). Confocal microscopy experiments revealed that MS4A4A and dectin-1 colocalization was notably increased by the dectin-1 agonist zymosan, which also induced an important increase in the colocalization index of both MS4A4A and dectin-1 with the lipid rafts tracer cholera toxin B-subunit (CT-B) ( Fig. 5e-h ). Super-resolution stimulated emission-depletion (STED) microscopy further confirmed increased colocalization of MS4A4A and dectin-1 on zymosan stimulation, as well as increased colocalization of both proteins with CT-B ( Fig. 5i-k) . Interestingly, treatment with the cholesterol-depleting agent methyl-β-cyclodextrin completely abrogated the zymosan-induced increase in dectin-1 colocalization with MS4A4A ( Fig. 5i-l) . Taken together, these results indicate that, on exposure to dectin-1 agonists, MS4A4A and dectin-1 colocalize in lipid rafts on the macrophage plasma membrane, suggesting a functional relevance of MS4A4A to dectin-1 signaling.
Ms4a4a is required for dectin-1 signaling activity. We next investigated the role of Ms4a4a in dectin-1 function. Dectin-1 was similarly expressed on BMDMs generated from Ms4a4a -/-and wildtype mice, and no difference was observed in the rate of dectin-1 internalization induced by its agonist zymosan (Fig. 6a) . Similarly, binding of zymosan-FITC particles was identical in BMDMs generated from Ms4a4a -/-and wild-type animals ( Fig. 6b ). Ms4a4a expression was also not relevant to dectin-1 internalization and phagocytosis when Aspergillus fumigatus conidia were used (Fig. 6c) .
To investigate the relevance of Ms4a4a for dectin-1 signaling, phosphorylation events for the three main signaling pathways acting downstream of dectin-1 (Syk, p38 and ERK) were assessed in BMDMs generated from Ms4a4a -/-and wild-type mice. On zymosan challenge, only Syk phosphorylation was significantly reduced in Ms4a4a
-/-compared with wild-type BMDMs (Fig. 6d) , whereas ERK and p38 phosphorylation was unaffected (Fig. 6e,f) . Similar results were obtained when curdlan and depleted zymosan, two dectin-1-specific agonists, were used, but not when BMDMs were stimulated with phorbol 12-myristate 13-acetate (PMA) (see Supplementary Fig. 6a-c) . Neither p38 nor ERK phosphorylation was influenced by Ms4a4a expression with any of the stimuli used (see Supplementary Fig. 6d ,e). In accordance with reduced Syk phosphorylation, on zymosan challenge Ms4a4a -/-BMDMs released fewer proinflammatory cytokines, including IL-6 and tumor necrosis factor, and produced fewer reactive oxygen species compared with wild-type BMDMs ( Fig. 6g-i ). The same defect was observed when depleted zymosan and curdlan were used (see Supplementary Fig. 6f ,g,i,j). Of note, the absence of Ms4a4a did not impact on cytokine production by BMDMs stimulated with toll-like receptor agonists, such as LPS (Fig. 6g,h ) or Pam3Cys (see Supplementary Fig. 6h ,k). Taken together, these results indicate that Ms4a4a is dispensable for dectin-1-mediated microbial recognition and phagocytosis, but is required to support optimal Syk phosphorylation and production of inflammatory cytokines and reactive oxygen species after engagement of dectin-1.
Ms4a4a contributes to dectin-1-mediated protection against metastasis. Dectin-1 has recently been shown to allow DC/macrophage-dependent recognition of tumor-associated molecular patterns on some tumor cells 13 . This dectin-1-mediated recognition pathway was shown to have an impact on the metastatic potential of the low metastatic B16F1 melanoma cells. Conversely, this pathway had no relevance for the metastatic potential of the highly metastatic B16F10 melanoma cells, which were found to be negative for the appropriate N-glycan structures recognized by dectin-1 13 . In accordance with this evidence, we observed a higher binding of wheat germ agglutinin (WGA), which recognizes N-acetylglucosamine residues, on the surface of B16F1 cells compared with B16F10 cells (Fig. 7a) . As shown for the pathogen-derived dectin-1 agonists, the tumor B16F1 cells could trigger Syk phosphorylation and cytokine production by BMDMs. Importantly, both Syk phosphorylation and IL-6 secretion induced by B16F1 cells were reduced in Ms4a4a -/-compared with wild-type cells (Fig. 7b,c) .
Prompted by this observation, we assessed the relevance of dectin-1 and Ms4a4a expression in macrophages for the metastatic potential in vivo of B16F1 and B16F10 cells. In agreement with earlier observations 13 , B16F1 cells showed a much higher metastatic potential in dectin-1-deficient animals (Clec7a -/-) compared with wild-type mice, whereas no difference was observed in the number of metastases generated by B16F10 cells (Fig. 7d,e, respectively) . Similar to previous observations on dectin-1-deficient animals 13 , macrophage-specific Ms4a4a deletion had no effect on the metastatic spread of B16F10, but resulted in a notable increase in the number of B16F1 metastases, the metastatic potential of which became comparable to that of B16F10 (Fig. 7f,g , and see Supplementary  Fig. 7a ). Of note, the number of B16F1 metastases was not further increased when mice double deficient for Msa4a4 and dectin-1 (Ms4a4a
Clec7a
-/-) were used, consistent with the idea that the two molecules cooperate in a common recognition pathway (see Supplementary Fig. 7b ). Importantly, the increased B16F1 metastatic spread observed in the absence of dectin-1 or Ms4a4a was also evident when N-glycan-depleted B16F1 cells were injected into wildtype animals (Fig. 7h) . Similar experiments were then performed with two colon carcinoma cell lines that exhibit different metastatic potential. As observed for B16 cells, the low metastatic MC38 cells showed high WGA binding and an increased number of Results are shown as mean ± s.e.m. Two biologically independent experiments were performed (11 mice). There was no statistical difference at any time point using the two-tailed, unpaired, Student's t-test. i,j, Tumor volume (i) and incidence (j) of 3-methylcholanthrene (3-MCA)-induced fibrosarcoma in Ms4a4a -/-(open symbol) and wild-type (closed symbol) mice. Results are shown as mean ± s.e.m Two biologically independent experiments were performed (16 mice). There was no statistical difference at any timepoint using the two-tailed, unpaired, Student's t-test.
metastases when injected into both Clec7a
-/-and Ms4a4a -/-mice compared with wild-type mice (see Supplementary Fig. 8a,b,d) . Conversely, the highly metastatic SL4 cells, which showed lower WGA binding compared with MC38 (see Supplementary Fig. 8a ), generated the same number of metastases in both Clec7a -/-and Ms4a4a -/-animals compared with wild-type animals (see Supplementary Fig. 8c,e) . Taken together, these results suggest that the expression of Ms4a4a on macrophages is required for dectin-1-mediated control of the metastatic spread of highly N-glycosylated tumor cells.
In vitro experiments have identified NK cells as effector cells in B16F1 killing 13 . Consistent with this, NK cell depletion by the use of an anti-NK1.1 antibody resulted in a large increase in B16F1 lung metastases and abrogated the difference observed between Ms4a4a -/-and wild-type animals (Fig. 8a,b) . Conversely, NK cell depletion did not abrogate the difference observed in the number of MC38 liver metastases (see Supplementary Fig. 8d ). As confocal microscopy analysis showed that NK cells and macrophages were located in close proximity to B16F1 lung metastases, suggesting possible cross-talk between NK cells and macrophages in metastatic lesions (see Supplementary Fig. 7c ), we then investigated the role of macrophage Ms4a4a in NK cell activation. Although Ms4a4a deletion had no impact on the abundance of NK cells and macrophages in the lungs bearing B16F1 metastatic lesions ( + cells in a degranulation assay, was considerably lower when B16F1 cells were cultured with splenocytes from Ms4a4a -/-mice compared with the wild-type counterpart (Fig. 8d) . Of note, defective activation of NK cells was not observed when B16F10 cells were used as targets (see Supplementary Fig. 7h ).
Previous studies suggested that dectin-1 triggering by tumor cells induces the expression on macrophage plasma membrane of the calcium homeostasis modulator family member 6 (CALHM6), also known as IFN regulatory factor 3-dependent NK-activating molecule (INAM), which in turn promotes NK cell activation, leading to tumor cell killing 13 . Consistent with this, the induction of Calhm6 expression in BMDMs cocultured with B16F1 cells was defective when Ms4a4a -/-cells were used (Fig. 8e) . A similar defect was observed when dectin-1 ligands were used, but not when BMDMs were activated using LPS (see Supplementary Fig. 7i,j,k) . The lack of Ms4a4a also affected the cytokine profile induced in BMDMs by tumor cell recognition. Although induction of Il12p40 after B16F1 engagement did not require Ms4a4a expression on BMDMs (Fig. 8f) , Ms4a4a -/-BMDMs expressed notably fewer Il15 and Il18 transcripts compared with wild-type BMDMs (Fig. 8g,h,  respectively) . A similar defect was evident when BMDMs were stimulated with zymosan (see Supplementary Fig. 7l ). In accordance with this finding, IFN-γ production by NK cells was much lower when B16F1 cells were cocultured with Ms4a4a -/-splenocytes compared with wild-type littermates (Fig. 8i) . Taken together, these results are consistent with a non-redundant role for Ms4a4a 
Discussion
MS4A4A is a member of the MS4A family, encoded in a 600-kb region on chromosome 11q12-13 in the human and chromosome 19 in the mouse genome 14, 15 . MS4A4A has been reported by us and others as a macrophage-restricted transcript associated with M2/M2-like polarization, and genome-wide association studies have correlated single nucleotide polymorphism variants within the MS4A4A/MS4A6A locus with late-onset Alzheimer's disease and cutaneous systemic sclerosis 16 . Recent studies have described MS4A4A as a chemosensor expressed by necklace sensory neurons 17 and a partner of the receptor tyrosine kinase KIT in mast cells 18 , but its function in macrophages is unknown. 
Ms4a4a
-/-mice). Statistical analysis was by two-tailed, unpaired (Mann-Whitney), Student's t-test. g,h, Secretion of IL-6 (g) and tumor necrosis factor (h) after stimulation for 6 h with 100 μg ml -1 zymosan or 100 ng ml -1 LPS. Cytokine levels in untreated cells were below the detection limit. Results are shown as mean ± s.e.m. Four biologically independent experiments were performed (g, seven wild-type and seven Ms4a4a -/-mice for zymosan; six wild-type and seven Ms4a4a -/-mice for LPS; h, seven wild-type and six Ms4a4a -/-mice for zymosan, seven wild-type and eight Ms4a4a -/-mice for LPS). Statistical analysis was by two-tailed, unpaired (Mann-Whitney), Student's t-test. i, Reactive oxygen species production after stimulation with 100 μg ml -1 zymosan. Results are shown as MFI as mean ± s.e.m. (six wild-type and six Ms4a4a -/-mice). Statistical analysis was by two-tailed, unpaired, Student's t-test.
MS4A proteins are characterized by a common structural organization based on four putative, highly hydrophobic, transmembrane domains, two extracellular loops and short, cytoplasmic N-and C-terminals, tightly resembling tetraspanins 19 . Tetraspanins, a large family of cell-surface proteins with a similar structural organization, are known to establish homo-and heterocomplexes called tetraspanin-enriched microdomains, in which they engage in lateral interactions with different partners, influencing their trafficking and signaling properties 11, [20] [21] [22] . Of note, some MS4A proteins, including CD20/MS4A1, FcεR1β/MS4A2 and the highly MS4A4A-related protein MS4A4B, have been shown to enter oligomeric complexes in lipid rafts, where they interact and influence signaling properties of associated partners 12, 23, 24 . Furthermore, MS4A4A has been reported to regulate the signaling activity of the receptor tyrosine kinase KIT, controlling its endocytic recycling and degradation pathways by a mechanism that involves colocalization of KIT with caveolin-1 in lipid rafts in mast cells 18 . In the present study we have demonstrated that, after dectin-1 engagement by zymosan, dectin-1 and MS4A4A translocate in lipid rafts on the macrophage plasma membrane. Of note, dectin-1 has already been reported to interact with tetraspanins, which control its availability on the plasma membrane and the quantity of cytokines produced after zymosan engagement 25 . Finally, we also provided evidence of MS4A4A association with itself and with MS4A6A and MS4A7, the other two members of the MS4A family with a macrophage-restricted expression pattern, and showed that, in the absence of MS4A4A expression, the signaling properties of dectin-1 are affected. Taken together, our results suggested that these three MS4A proteins might contribute to the organization of specific microdomains on the plasma membrane of macrophages where signaling properties of membrane receptors, including dectin-1, are regulated.
Dectin-1 is a pattern recognition receptor belonging to the nonclassic, C-type lectin, receptor family 26 . Dectin-1 plays a pivotal role in controlling a wide range of fungal infections, including species of Candida, Aspergillus, Pneumocystis and Coccidioides 26, 27 . More recently, a role for dectin-1 in the resistance to a broader range of microorganisms, in autoimmunity and in tumor cell recognition, has also been recognized 28 . The signaling activity of dectin-1 after ligand engagement requires clustering into a phagocytic synapse 29 and results in enhanced phagocytosis, respiratory burst activity and inflammatory cytokine secretion 30, 31 . The dectin-1 signaling pathway in macrophages is still ill-defined [32] [33] [34] . It has, however, been demonstrated that dectin-1 signaling activity in macrophages is delayed compared with DCs, and that it leads to both Syk-independent and Syk-dependent signaling pathways, which control phagocytosis and production of effector molecules (cytokines and reactive oxygen species), respectively 32, [35] [36] [37] . Our evidence that Ms4a4a-deficient macrophages show normal phagocytic properties, but reduced Syk phosphorylation and impaired cytokine and reactive oxygen species production, indicates that MS4A4A is functionally relevant for the Syk-dependent signaling pathway in macrophages. In macrophages, MS4A4A expression was significantly increased by IL-4 and, intriguingly, glucocorticoids. In patients with Graves' disease treated with methylprednisolone, MS4A4A induction was observed in circulating monocytes, thus providing an in vivo confirmation of the regulation found in vitro. Glucocorticoid hormones are potent regulators of immunity and inflammation, and macrophages are a prime target for their action under physiologic and pharmacologic conditions 38 . Glucocorticoid hormones not only suppress inflammatory cytokines production, but also orchestrate tissue remodeling and reshape macrophage functions with the induction of anti-inflammatory molecules such as the IL-1 decoy receptor IL-1R2 (ref. 39 ) and selected chemokines 40 . Moreover, glucocorticoid hormones have been suggested to set components of the innate immune system in an alert mode, priming for immediate/early responses to pathogens 38 . Given the coupling of MS4A4A with a microbial sensor, its induction could be a component of this early aspect of the pathophysiology of glucocorticoid hormones. Irrespective of its significance, monocyte expression of MS4A4A could serve as a biomarker of the response of mononuclear phagocytes to these agents.
Macrophages have been shown to promote activation of NK cell anti-tumoral activities through direct cell-cell contacts or soluble mediators, including IL-15 and IFN-β 41, 42 . In this setting, recent evidence in a melanoma model indicates that macrophage recognition of tumor cell-associated molecular patterns via dectin-1 is associated with a reduction of tumor burden and metastatic spread due to the activation of cytotoxic NK cells 13 . NK cells are known to play a major role in resistance against hematologic neoplasms, whereas their role in solid tumors is usually considered less . Recent results challenge this long-held view by showing that inactivation of the NK cell checkpoint IL-1R8 unleashes NK cell-mediated resistance against carcinogenesis at NK cell-rich anatomical sites, such as the liver and lung 44 . In line with this general view, results reported here indicate that, when macrophages are engaged via dectin-1 with B16F1 melanoma cells, the absence of Ms4a4a impairs their ability to upregulate CALHM6/INAM, secrete IFN-γ-inducing cytokines and trigger NK cell-mediated cytotoxic response, thus hampering the ability of NK cells to control tumor metastases to the lung. Considering this evidence and the observation that MS4A4A is barely detectable in the various subsets of circulating monocytes, and induced during their differentiation to macrophages, we conclude that MS4A4A expression on TAMs is likely required to support the interaction between NK cells and TAMs observed in metastatic foci, where this cross-talk activates NK cell-mediated tumor cell killing. MS4A4A therefore does not contribute to the pro-tumoral functions of TAM infiltrating primary tumors and, conversely, its expression in macrophages at metastatic sites is required for appropriate NK cell-mediated, anti-tumoral functions. These results are well in line with previous results by us and others showing that the organ immunologic context is indeed a key determinant of effective anti-tumor effector mechanisms 45 , with divergent impact of immune manipulations on primary versus metastatic tumors 46, 47 . There is evidence that the tissue texture contributes to shaping the microenvironment of tumors originating in different organs 4 . Moreover, complex and diverse mechanisms orchestrate the formation of metastatic niches at sites of secondary localization of tumors 48 . Accordingly, it has long been known that immune mechanisms can have a divergent impact on primary tumors and metastasis 3, 47 , as shown here for the MS4A4A-dectin-1 interaction. Thus, in a therapeutic perspective, pathways of immune resistance at sites of secondary localization should be taken into account.
Several studies are ongoing with the aim of targeting TAMs as a promising immune strategy to impact on tumor biology 3, 49 . MS4A4A belongs to the same protein family as CD20 (also known as MS4A1) 14 , the targeting of which by specific monoclonal anti bodies has proven to be effective for the treatment of and autoimmune disorders 50 . Thus, from a translational perspective, our discovery of MS4A4A as a new M2/TAM marker raises the interesting possibility that it may represent a valid target for TAM depletion, although the anti-tumoral effect has to be balanced with the negative impact on spreading metastases that we have shown here. Finally, targeting the MS4A4A/dectin-1 interaction may allow fine-tuning of uncontrolled, pathogen-triggered, innate immune responses.
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Methods
Cells.
Human peripheral blood mononuclear cells were isolated from buffy coats of healthy donors and monocytes were obtained by serial centrifugation as described 6 and approved by the institutional Ethical Committee of the Humanitas Clinical and Research Center. Monocytes were treated for 7 d with 50 ng ml -1 recombinant human (rh) granulocyte-macrophage colony-stimulating factor (rhGM-CSF) (Miltenyi Biotech) plus 40 ng ml -1 rhIL-4 (Peprotech) to obtain DCs, and with 100 ng ml -1 rhM-CSF (R&D Systems) to obtain macrophages. Macrophages were activated in vitro by 18 h incubation with either 100 ng ml 
/CD11b
+ TAMs and PECs were sorted using an Influx flow sorter (BD Bioscience) and immediately lysed for RNA extraction. B16F1 and B16F10 cells were cultured in RPMI (Roswell Park Memorial Institute) 1640, 10% FBS, 1% l-glutamine, 1% penicillin/streptomycin, 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) (Lonza). B16F1 cells were induced to apoptosis by 5 min heat shock at 65 °C followed by 5 min on ice. MC38 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Lonza), 10% FBS, 1% l-glutamine, 1% penicillin/ streptomycin, 1% sodium pyruvate, 1% non-essential amino acids (Lonza). SL4 cells were cultured in DMEM:F12 (1:1) medium (Lonza), 10% FBS, 1% l-glutamine, 1% penicillin/streptomycin. Chinese hamster ovary K1 cells were grown in DMEM, 10% FBS, 100 U ml -1 penicillin/streptomycin and 25 mM Hepes pH 7.2 (Gibco). Transfectants were obtained by lipofection with Lipofectamine 2000 according to the manufacturer's instructions, and selected with 650 μg ml -1 G418 (Invitrogen).
Patients' samples.
Monocytes from patients with active, severe, Graves' disease orbitopathy were collected before and 6 h after the first intravenous infusion of 1 g methylprednisolone. A signed informed consent for blood/serum collection and storage and for its use for research purposes was obtained by the Endocrinology Unit, Fondazione IRCCS Ca' Granda Policlinico. In agreement with the institutional policy, the Ethical Committee approval was not required, because patients did not undergo tests or therapies other than those routinely proposed for their specific disease. RA synovium samples were retrieved from early (<12 months of symptoms) patients fulfilling the American College of Rheumatology/European League Against Rheumatism 2010 criteria 51 for RA diagnosis, recruited into the Pathobiology of Early Arthritis Cohort (http://www.peac-mrc.mds.qmul.ac.uk/) at Bart's Health NHS Trust in London. After obtaining written informed consent, patients underwent an ultrasound-guided needle synovial biopsy of the most inflamed accessible joint 52 . Synovial tissue samples were immediately fixed in 4% formaldehyde (Merck) and subsequently paraffin embedded. The study was approved by the institutional Ethical Committee (no. 05/Q0703/198). Histological analysis of normal and tumoral tissue samples was performed on material obtained from the Surgical Pathology Unit, ASSTSpedali Civili in Brescia. Experiments performed on archival material were approved by the institutional Ethical Committee (WV-Immunocancer 2014 to WV, IRB code NP906). When requested, an informed consent was obtained from all participants.
Immunohistochemical and immunofluorescence analysis. MS4A4A expression was analyzed on 4-μm formalin-fixed, paraffin-embedded sections of normal tissues (skin, lung, colon) and corresponding neoplastic samples (five melanomas, five lung adenocarcinomas, five colon adenocarcinomas) by staining with anti-human MS4A4A (rabbit polyclonal, dilution 1:4,000; Sigma-Aldrich) and revealing using Novolink Polymer (Leica Biosystems) as the secondary reagent. The chromogen reaction was developed using diaminobenzidine. For double immunostains, MS4A4A was combined with CD1c (clone OTI2F4; Abcam), CD163 (clone 10D6; Thermo Fisher Scientific), CD207 (clone 12D6; Vector Laboratories) and CD303 (clone 124B3.13; Dendritics). The second antibody reactivity was detected using a Mach 4 alkaline phosphatase system with Ferangi Blue (Biocare Medical) as the chromogen. Slides were counterstained with hematoxylin. Omission of primary antibody was also performed as control staining. Immunostained sections were photographed using the DP73 Olympus digital camera mounted on the Olympus BX60 microscope and analyzed using the acquisition software CellSens Standard. Images were then processed using Adobe Photoshop Cs4 Portable. MS4A4A expression on inflamed synovium was performed on 3-μm formalin-fixed, paraffinembedded sections obtained from five patients by multiplex immunofluorescence staining using a tyramide signal amplification protocol and an anti-MS4A4A, rabbit polyclonal, anti-human antibody (dilution 1:2,000; Sigma-Aldrich) in combination with CD68 (mouse anti-human immunoglobulin (Ig)G1, clone KP1; Dako), CD163 (mouse anti-human IgG1, clone 10D6; Leica Biosystems), CD3 (mouse anti-human IgG1, clone F7.2.38; Dako), CD20 (mouse anti-human IgG2a, clone L26; Dako) and CD138 (mouse anti-human IgG1, clone MI15; Dako). Matching isotypes were used as controls. Nuclei were counterstained with DAPI (300 nM; Invitrogen) and mounted with ProLong Antifade Mountant (Thermo Fisher Scientific). Sections were imaged with the digital slide scanner Nanozoomer S60 (Hamamatsu Photonics). The quantification of CD68/MS4A4A/CD163 + cells was performed using the cell count plugin of the ImageJ software. TAMs and NK cells infiltrating experimental metastases were analyzed on frozen sections (10-μm thick) obtained from tissue blocks of B16F1 metastases-bearing lungs. Sections were thawed and fixed with 4% paraformaldehyde for 5 min, washed and incubated for 15 min in phosphate-buffered saline supplemented with 0.05% Tween-20, 2% BSA, 5% donkey serum (SigmaAldrich), and incubated for 1 h with purified polyclonal goat anti-mouse NKp46 (R&D Systems), rat anti-mouse F4/80 (Serotech) and rabbit anti-mouse Ki-67 (Cell Signaling). After extensive washing, sections were incubated for 1 h with Alexa Fluor (488, 568, 647)-conjugated, species-specific, cross-adsorbed, detection antibodies (Molecular Probes). Nuclei were stained using DAPI. Sections were mounted with 20 μl FluorSave reagent (Calbiochem). Fluorescent high-resolution images were acquired with a Leica SP8 STED ×3 confocal microscope (Leica HC PL APO ×60/1.40 oil STED white objective system) and analyzed using LAS-X software. /2 J from Jackson Laboratory). Animals were housed in ventilated cages in a specific pathogen-free/ viral antibody-free animal facility at Humanitas Clinical and Research Center. Experiments were performed using sex-and age-matched mice.
Experimental models. The 3-methylcholanthrene-induced tumor model was performed using 100 μg 3-methylcholanthrene as previously described 53 . In the melanoma B16F1 model, tumor dimension was monitored in mice subcutaneously injected with 0.1 × 10 6 B16F1 cells as previously described Split-ubiquitin assay. The split-ubiquitin assay was performed as previously described 12 . Briefly, a split-ubiquitin NubG-X library, derived from monocytederived human macrophages treated with 10 −6 M Dex, was directionally cloned into the prey vector pBT3-N and the bait protein MS4A4A complementary DNA was cloned into the bait vector pBT3-STE, in which the LexA-VP16-Cub cassette is fused to the N terminus. The yeast strain NMY51 (MATa his3-200 trp1-901 leu2-3,112 ade2 LYS2::(lexAop)4-HIS3 ura3::(lexAop)8-LacZ ade2::(lexAop)8-ADE2 GAL4) was transformed using standard procedures. Transformants were grown on selective medium lacking leucine, tryptophan, histidine and adenine, with addition of 20 mM 3-amino-1,2,4-triazole. Positive clones were sequenced by colony PCR (pPR3N-FOR: 5′-GTCGAAAATTCAAGACAAGG-3′; pPR3N-REV: 5′-AAGCGTGACATAACTAATTAC-3′). Library plasmids were isolated from positive clones and retransformed into NMY51 to test bait dependency. Prey sequences activating the histidine and adenine reporters in the presence of MS4A4A, and not the empty pBT3-STE vector, were considered as potential MS4A4A interactors.
